
Ensartinib dihydrochloride
A potent and selective anaplastic lymphoma kinase (ALK) inhibitor primarily indicated for the treatment of specific types of non-small cell lung cancer (NSCLC).
Overview
Ensartinib dihydrochloride is a potent oral small-molecule anaplastic lymphoma kinase (ALK) inhibitor, with the effect of inhibiting the activity of ALK and its fusion proteins. Ensartinib dihydrochloride can be used for the research on ALK-positive non-small cell lung cancer (NSCLC), ALK fusion gene-related malignant tumors, and drug-resistant ALK-mutated tumors.
Synonyms: Ensartinibdihydrochloride; Ensartinibhydrochloride; X-396hydrochloride; Ensartinibhydrochloride(X396); X-396dihydrochloride; Ensartinib, X396, Clusterofdifferentiation246, X396, Inhibitor, CDChemicalbook246, Anaplasticlymphomakinase(ALK), Anaplasticlymphomakinase, c-Met/HGFR, ALKtyrosinekinasereceptor, Ensartinibhydrochloride, inhibit, X-396; Ensartinib2HCl; Ensartinib(X-396)dihydrochloride
Product Categories: APIS
Mol File: 2137030-98-7.mol
Physicochemical Properties
Storage temp: 0-4℃ for short term (days to weeks), or -20℃ for long term (months).
Solubility: Chloroform (Slightly, Heated), Methanol (Slightly, Heated)
Form: Solid
Color: White
MSDS Information
Experimental Data
1. Cell Experiment
Solubility in DMSO : 35.71 mg/mL (56.29 mM; ultrasonic co-solubilization; Hygroscopic DMSO has a significant effect on the solubility of the product, use freshly opened DMSO); H2Solubility in O : 33.33 mg/mL (52.54 mM; Ultrasonic Assisted Lysis)
Preparing Stock Solutions:

Please choose the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; Once prepared into a solution, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and duration of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。 Use within 6 months when stored at -80°C, and within 1 month when stored at -20°C.Note: If you choose water as the stock solution, dilute it to the working solution and filter it with a 0.22 μm membrane before use.
2. Animal Control
Choose the appropriate dissolution protocol based on your experimental animal and mode of administration.
For the following dissolution schemes, please prepare the clarified stock solution according to the in vitro method, and then add the co-solvent in turn:
- In order to ensure the reliability of the experimental results, the clarified stock solution can be properly stored according to the storage conditions; It is recommended that you use the working solution for in vivo experiments and use it on the same day;The percentages shown before the following solvents are the proportion of the volume of that solvent in your final solution; If precipitation and precipitation occur during the preparation process, it can be dissolved by heating and/or ultrasound.
Option 1
Add each solvent in order: 10% DMSO,40% PEG300 , 5% Tween-80, 45% Saline.
Solubility:≥ 2.08 mg/mL (3.28 mM); Clarifying solution.
A clarified solution of ≥ 2.08 mg/mL (saturation unknown) is obtained for this protocol.
For example, take 1 mL of working solution and add 100 μL of 20.8 mg/mL of clarified DMSO stock solution to 400 μL of PEG300 and mix well. Add 50 μL of Tween-80 to the above system and mix well; Then proceed with 450 μL of normal saline to 1 mL.
Preparation of normal saline: 0.9 g of sodium chloride dissolved in ddH₂O and fixed to 100 mL can obtain a clear and transparent normal saline solution.
Option 2
add each solvent in order:10% DMSO,90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.28 mM); Clarifying solution
A clarified solution of ≥ 2.08 mg/mL (saturation unknown) is obtained for this protocol.
For example, 100 μL of 20.8 mg/mL of clarified DMSO stock solution is added to 900 μL of 20% SBE-β-CD saline in water and mixed well.
Option 3
add each solvent in order:10% DMSO,90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.28 mM); Clarifying solution
A clarified solution of ≥ 2.08 mg/mL (saturation unknown) is available for use in animal experiments with an experimental period of more than half a month, as appropriate.
For example, 100 μL of 20.8 mg/mL of clarified DMSO stock solution was added to 900 μL of corn oil and mixed well.
Pharmacodynamics
Mechanism Of Action
Similar Products

Carboplatin
Therapy
: Oncology
Target
: DNA
CAS
: 41575-94-4
MF
: C6H12N2O4Pt
MW
: 371.25

Letrozole
Therapy
: Oncology
Target
: ERs;Aromatase
CAS
: 112809-51-5
MF
: C17H11N5
MW
: 285.3

Oxaliplatin
Therapy
: Oncology
Target
: DNA
CAS
: 61825-94-3
MF
: C8H12N2O4Pt
MW
: 395.28

Lazertinib
Therapy
: Oncology
Target
: EGFR ; EGFR T790M ; EGFR L858R ; EGFR 19del
CAS
: 1903008-80-9
MF
: C30H34N8O3
MW
: 554.64
